Drugs, their targets and the nature and number of drug targets

@article{Imming2006DrugsTT,
  title={Drugs, their targets and the nature and number of drug targets},
  author={Peter Imming and Christian Sinning and Achim Meyer},
  journal={Nature Reviews Drug Discovery},
  year={2006},
  volume={5},
  pages={821-834}
}
What is a drug target? And how many such targets are there? Here, we consider the nature of drug targets, and by classifying known drug substances on the basis of the discussed principles we provide an estimation of the total number of current drug targets. 
Drugs, their targets and the nature and number of drug targets
TLDR
This work considers the nature of drug targets, and by classifying known drug substances on the basis of the discussed principles it provides an estimation of the total number of current drug targets. Expand
What makes a good drug target?
TLDR
Key properties of a good drug target from the perspective of a pharmaceutical company are defined. Expand
Trends in the exploitation of novel drug targets
TLDR
The drugs that were approved by the US Food and Drug Administration during the past three decades are analysed and the interactions of these drugs with therapeutic targets that are encoded by the human genome are examined, using the DrugBank database and extensive manual curation. Expand
Bioinformatic studies of the disposition pathways and targets of synthetic drugs and herbal medicines
TLDR
Drugs are pharmaceutical compounds administered to treat or diagnose disease and have specific reactions with molecular structures or drug targets to produce an effect. Expand
Discovery: Use of Systems Biology for Identifying Targets
TLDR
It is emphasized that a combination of reductionist (mechanism- based) and holistic (hypothesis-based) tools in the drug screening process may increase the efficiency of overall Drug Discovery. Expand
The Role of Chemical Biology in Drug Discovery
TLDR
This article will highlight some critical contributions from chemical biology methods in the context of a high-level overview of drug discovery as practiced currently. Expand
How were new medicines discovered?
TLDR
It is postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development. Expand
Drug profiling: knowing where it hits.
TLDR
Current and promising drug profiling alternatives and commercial solutions in these exciting emerging fields are reviewed. Expand
The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication.
TLDR
A data set of clinical trial drug-target interactions based on CenterWatch's Drugs in Clinical Trials Database, one of the largest databases of its kind, is developed, identified 475 potentially novel clinical trialDrug targets currently being explored in clinical trials. Expand
Chapter 41 – Modern Drug Discovery and Development
TLDR
This chapter presents an overview of the drug discovery and development process from the laboratory bench through postmarketing approval, including aspects of drug discovery include discovering drug targets, identifying and optimizing lead compounds, preclinical studies, and phase 1 through phase 4 clinical studies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 280 REFERENCES
A classification of drug substances according to their mechanism of action.
TLDR
An alternative classification system (TCAT: Target-Chemistry-Anatomy-Therapy) is proposed which refers to the molecular mechanism of action or rather, target, which may be particularly useful in teaching advanced medicinal chemistry. Expand
Biochemical mechanisms of drug action: what does it take for success?
  • D. Swinney
  • Biology, Medicine
  • Nature Reviews Drug Discovery
  • 2004
TLDR
Potential drug discovery and development risks associated with the biochemical mechanism of drug action are addressed, and simple rules to minimize these risks are proposed. Expand
The druggable genome
An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceuticalExpand
Drug discovery: Playing dirty
Forget drugs carefully designed to hit one particular molecule — a better way of treating complex diseases such as cancer may be to aim for several targets at once, says Simon Frantz.
Illuminating drug discovery with biological pathways
TLDR
A “systems” approach can help identify pathways related to a disease and can suggest secondary effects of drugs that might cause these problems and thus ultimately improve the drug discovery pipeline. Expand
Multicomponent therapeutics for networked systems
TLDR
A focus in the early drug discovery process on identifying and optimizing the activity of combinations of molecules can result in the identification of more effective drug regimens. Expand
Knockouts model the 100 best-selling drugs—will they model the next 100?
TLDR
A retrospective evaluation of the knockout phenotypes for the targets of the 100 best-selling drugs indicates that these phenotypes correlate well with known drug efficacy, illuminating a productive path forward for discovering future drug targets. Expand
Chemistry, Biology, and Medicine of the Glycopeptide Antibiotics.
The war against infectious bacteria is not over! Although vancomycin and glycopeptide antibiotics have provided a strong last line of defence against many drug-resistant bacteria, their overuse hasExpand
Drugs targeting the ribosome.
  • T. Hermann
  • Biology, Medicine
  • Current opinion in structural biology
  • 2005
TLDR
Three-dimensional structures of ribosome-antibiotic complexes have been determined, providing a detailed picture of the binding sites and mechanism of action of antibacterials, including 'blockbuster' drugs such as the macrolides. Expand
Mechanistic basis of enzyme-targeted drugs.
TLDR
The variety of inhibition mechanisms for enzyme-targeted drugs are reviewed, an enzyme target database for drugs currently marketed in the United States is established, and advanced methods for determining transition-state structure now offer the opportunity for direct drug design without resorting to expensive random testing campaigns. Expand
...
1
2
3
4
5
...